Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 88 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2014', provides an overview of the Leishmaniasis (Kala-Azar)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Leishmaniasis (Kala-Azar) Overview 9
Therapeutics Development 10
Pipeline Products for Leishmaniasis (Kala-Azar) - Overview 10
Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis 11
Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies 12
Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes 14
Leishmaniasis (Kala-Azar) - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Leishmaniasis (Kala-Azar) - Products under Development by Companies 18
Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes 19
Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development 20
Sanofi 20
Takeda Pharmaceutical Company Limited 21
Zydus Cadila Healthcare Limited 22
Merck KGaA 23
iCo Therapeutics Inc. 24
Mologen AG 25
Advinus Therapeutics Ltd. 26
Dafra Pharma International Ltd. 27
PolyTherics Limited 28
Leishmaniasis (Kala-Azar) - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
fexinidazole - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
leishmaniasis vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NPC-1161B - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
amphotericin b - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
LMP-400 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
MGN-1331 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Oleylphosphocholine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AS-605240 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
leishmaniasis vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
amphotericin b NanoDisk - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules for Leishmaniasis - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules for Infectious Diseases - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule for Leishmaniasis - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
S-010269 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecule for Leishmaniasis - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
VL-2098 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecule for Visceral Leishmaniasis - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
pegylated amphotericin B - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
amphotericin b - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Visceral Leishmaniasis Vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules for Visceral Leishmaniasis - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecules for Leishmaniasis, Chagas disease and HAT - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
corifungin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules to Inhibit Elongation Factor 1 Alpha for Leishmaniasis and Malaria - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecule for Leishmaniasis - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecules for Infectious Disease and Oncology - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CDRI-99/288 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Leishmaniasis Vaccine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecules for Protozoal Infections - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Leishmaniasis (Kala-Azar) - Recent Pipeline Updates 76
Leishmaniasis (Kala-Azar) - Dormant Projects 78
Leishmaniasis (Kala-Azar) - Discontinued Products 79
Leishmaniasis (Kala-Azar) - Product Development Milestones 80
Featured News & Press Releases 80
Mar 19, 2014: Knight Therapeutics Announces FDA Approval for Impavido (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis 80
Nov 11, 2013: Paladin Announces Extension of the Impavido� PDUFA Date by Three Months 80
Jun 19, 2013: Paladin Receives Priority Review Status From FDA For Impavido NDA Submission For Treatment Of Leishmaniasis 80
Dec 17, 2012: PATH's Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh 81
Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 82
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 82
Jan 09, 2012: Study Confirms New Strategy In Fight Against Infectious Diseases 83
Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS 84
Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status 85
Apr 06, 2010: MOLOGEN AG Receives Funding To Develop A DNA Vaccine Against Hepatitis B 85
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88

List of Tables
Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2014 10
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Leishmaniasis (Kala-Azar) - Pipeline by Sanofi, H2 2014 20
Leishmaniasis (Kala-Azar) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 21
Leishmaniasis (Kala-Azar) - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 22
Leishmaniasis (Kala-Azar) - Pipeline by Merck KGaA, H2 2014 23
Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H2 2014 24
Leishmaniasis (Kala-Azar) - Pipeline by Mologen AG, H2 2014 25
Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd., H2 2014 26
Leishmaniasis (Kala-Azar) - Pipeline by Dafra Pharma International Ltd., H2 2014 27
Leishmaniasis (Kala-Azar) - Pipeline by PolyTherics Limited, H2 2014 28
Assessment by Monotherapy Products, H2 2014 29
Number of Products by Stage and Target, H2 2014 31
Number of Products by Stage and Mechanism of Action, H2 2014 33
Number of Products by Stage and Route of Administration, H2 2014 35
Number of Products by Stage and Molecule Type, H2 2014 37
Leishmaniasis (Kala-Azar) Therapeutics - Recent Pipeline Updates, H2 2014 76
Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2014 78
Leishmaniasis (Kala-Azar) - Discontinued Products, H2 2014 79